ongitudinal analysis of tumor-specific T-cel immunity in irresectable stage IIIc and stage IV melanoma patients

Completed

• Conditions: melanoma; skin cancer; 10040900

• Registration Number: NL-OMON36481
• Lead Sponsor: eids Universitair Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 50

Inclusion Criteria

-Histologically or cytologically proven irresectable stage IIIc or IV melanoma
-Age above 18 years
-WHO performance score 0, 1 or 2 at the time of study entry
-Written informed consent

Exclusion Criteria

-Severe anemia (Hb < 6.0 mmol/L)

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Immunologic monitoring</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>None.</p><br>